Insulet (PODD) Cost of Revenue (2010 - 2026)

Insulet's Cost of Revenue history runs 17 years deep, the most recent figure standing at $232.7 million for Q1 2026.

• Quarterly Cost of Revenue rose 45.53% year-over-year to $232.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $841.0 million (up 29.21% YoY) and the FY2025 annual result came in at $768.2 million, up 22.74% from the prior year.
• Cost of Revenue was $232.7 million for Q1 2026 at Insulet, up from $215.2 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $232.7 million in Q1 2026 and bottomed at $85.7 million in Q1 2022.
• A 5-year average of $156.7 million and a median of $152.5 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 75.49% — and 2023, when it retreated 8.59%.
• Insulet's Cost of Revenue stood at $152.4 million in 2022, then retreated by 2.49% to $148.6 million in 2023, then climbed by 12.11% to $166.6 million in 2024, then grew by 29.17% to $215.2 million in 2025, then advanced by 8.13% to $232.7 million in 2026.
• Business Quant data shows PODD's Cost of Revenue at $232.7 million in Q1 2026, $215.2 million in Q4 2025, and $196.2 million in Q3 2025.